FOXO4-DRI Benefits: Counted by Organism, Not by Claim

FOXO4-DRI benefits, counted by organism

Claim	What was measured	Organism	Studies
Clears senescent cells	Selective apoptosis via FOXO4 and p53	Mouse, cultured cells	Several
Restores fitness	Physical performance in aged animals	Mouse	1
Restores fur density	Coat regrowth, photographed	Mouse	1
Improves renal function	Kidney markers in aged animals	Mouse	1
Protects against chemotoxicity	Doxorubicin damage neutralised	Mouse	1
Raises testosterone	Senescent Leydig cell clearance	Mouse	1
Improves spermatogenesis	Reduced inflammatory secretion	Mouse	1
Rejuvenates cartilage cells	Senescent cell removal in expansion	Human cells in a dish	1
Reduces lung fibrosis	Bleomycin-induced model	Mouse	1
Any benefit in a living person	Nothing measured	None	0

The bottom row is not an omission from the literature; it is the literature. ClinicalTrials.gov lists no registered interventional study of this peptide in humans.

What the foundational study actually reported

Nearly every claim originates in one 2017 paper from the de Keizer group at Erasmus MC in Rotterdam.

It identified FOXO4 as the protein keeping senescent cells alive by binding p53 and preventing apoptosis, then designed a peptide to displace that interaction. In living animals it showed three things: reduced doxorubicin toxicity in treated mice, and restored fitness, fur density and renal function in both fast-ageing XpdTTD/TTD mice and naturally aged animals.

Those results were striking enough for wide mainstream coverage, which is why the compound has a public profile at all. Photographs of treated mice regrowing fur circulated widely and are still repurposed online as though they showed something about people.

The mechanism has since been elaborated, notably by a 2025 paper identifying the disordered transactivation domain of p53 as the binding target. Mechanistic depth is not clinical evidence, and no trial has followed in nine years.

The in-vitro human study, and what it does not show

One study is routinely cited as human evidence and it is worth handling precisely, because the citation is real and the interpretation is not.

A 2021 paper applied FOXO4-DRI to human chondrocytes expanded in culture and reported selective removal of senescent cells. Those are genuinely human cells and the result is genuine.

They are also cells in a dish, with no circulation, no immune system, no clearance, no distribution and no organism-level consequences. In-vitro human cells sit closer to human relevance than a mouse on one axis and no closer at all on the axes that determine whether something works as a treatment. Presenting it as human evidence is the most common overstatement made about this compound.

The counterweight

Senescent cells are not simply refuse awaiting disposal. Senescence is a tumour-suppressive mechanism, removing cells carrying dangerous mutations from the replicative pool permanently. Senescent cells also appear transiently at wound sites and contribute to repair.

A 2023 study in Circulation reported that eliminating senescent cells could promote the development and progression of pulmonary hypertension. That is an experimental result running counter to the general enthusiasm, and it shows the effect depends heavily on tissue and context.

Set against an absence of any human safety data, the defensible summary is narrow: a real mechanism, a genuine preclinical result, and an entirely uncharacterised human profile.

Frequently Asked Questions

What are the proven benefits of FOXO4-DRI?expand_more

None are proven in humans, because no human trial has been conducted. In mice the 2017 study reported restored fitness, fur density and renal function in aged animals, plus protection against doxorubicin toxicity.

Has FOXO4-DRI been tested on human cells?expand_more

In culture, yes. A 2021 study applied it to human chondrocytes expanded in vitro and reported selective removal of senescent cells. That is human tissue in a dish, not evidence in a living person.

How many studies support each benefit?expand_more

Most claims rest on a single study in mice. Senescent-cell clearance itself is replicated across several models; the organ-level outcomes are largely single-study findings.

Are there downsides to clearing senescent cells?expand_more

Yes. Senescence suppresses tumour formation and contributes to wound healing. A 2023 Circulation study found that eliminating senescent cells could worsen pulmonary hypertension.

Worked Examples — Related Compound Protocols

Apply this guide to real protocols. Each linked page includes a live reconstitution calculator and titration schedule.

Epitalon dosage protocol

Epitalon (also Epithalon, Epithalamin tetrapeptide) is a synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) developed by Vladimir Khavinson by directed synthesis from the amino-acid composition of bovine pineal extract Epithalamin [1][2]. It is the most extensively studied of the Khavinson peptide bioregulators, with documented effects on telomerase activation, telomere elongation, melatonin restoration, and lifespan extension in rodent and Drosophila models [3][4][5]. Khavinson and colleagues showed Epitalon activates telomerase in human fetal somatic cell cultures with observable telomere elongation, and Anisimov demonstrated 12–13% lifespan extension in mice and 11–16% in fruit flies [6]. Standard research dosing is 5–10 mg subcutaneously per day for 10–20 consecutive days, repeated 2–3 times yearly. Epitalon is registered as a peptide bioregulator in Russia but is not approved by the FDA, EMA, or MHRA; outside Russia it is a research-only compound. Human clinical evidence is limited to Russian observational use in age-related disorders, with reports of restored circadian melatonin rhythms, improved immune markers, and normalized neuroendocrine function.

Open protocolarrow_forward

NAD dosage protocol

NAD+ (nicotinamide adenine dinucleotide) is the central redox and signaling cofactor for hundreds of enzymes including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38, with intracellular concentrations declining substantially with age across human tissues [1][2]. Sinclair, Imai, and colleagues established sirtuins as NAD-dependent deacetylases that regulate longevity, metabolism, and DNA repair, and showed that restoring NAD+ levels through precursor supplementation can reverse age-related metabolic decline in mice [3][4]. Yoshino and colleagues demonstrated in a randomized clinical trial that nicotinamide mononucleotide (NMN) at 250 mg/day improves muscle insulin sensitivity in prediabetic women [5]. NAD+ itself is administered as a research and integrative medicine intervention at 100–500 mg subcutaneously or intramuscularly, or 250–1000 mg by slow intravenous infusion over 1–4 hours, in cycles. NAD+ is sold as a supplement (oral, sublingual, injectable) but the FDA has not approved NAD+ injection for any therapeutic indication. NAD+ precursors (NR, NMN) have FDA NDI status as dietary supplements but are not approved drugs.

Open protocolarrow_forward

BPC-157 dosage protocol

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a partial sequence of a larger Body Protection Compound originally isolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s [1][2]. Across more than 30 years of preclinical work, BPC-157 has been shown to accelerate the healing of tendon, ligament, muscle, bone, skin, gastrointestinal tract, and cornea through pro-angiogenic mechanisms involving VEGF receptor 2 (VEGFR2) activation, nitric oxide synthase upregulation through the Akt-eNOS axis, ERK1/2 signaling, and modulation of the dopaminergic and serotonergic systems [3][4]. Chang and colleagues demonstrated in the Journal of Applied Physiology that BPC-157 promotes tendon healing by enhancing tendon outgrowth, cell survival, and migration in tendon fibroblast cultures, and that it upregulates growth hormone receptor expression in those cells [5][6]. BPC-157 is not FDA approved and remains a research peptide. Typical research dosing is 250 to 500 mcg/day subcutaneously, with cycles of 4 to 8 weeks.

Open protocolarrow_forward

References & Citations

[1]
Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16.View source →
[2]
Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16(1):5672.View source →
[3]
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021;9:677576.View source →
[4]
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284.View source →
[5]
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023.View source →